

Report to the
Health and Human Services
Interim Committee
and the
Social Services Appropriations
Subcommittee

Medicaid Preferred Drug List
Psychotropic Drugs

Prepared by the Division of Medicaid and Health Financing

November 2020



EXECUTIVE SUMMARY

UCA 26-18-2.4(3) authorized a PDL for psychotropic drugs with a dispense as written override and established targets for savings from the PDL.

This report is submitted in response to the following language from UCA 26-18-2.4(3):

(e) The department shall report to the Health and Human Services Interim Committee and the Social Services Appropriations Subcommittee before November 30, 2016, and before each November 30 thereafter regarding compliance with and savings from implementation of this Subsection (3).

Implementation of a Psychotropic PDL

The statute defines psychotropic medications as:

- i. Atypical Anti-psychotics;
- ii. Anti-depressants;
- iii. Anti-convulsant/mood stabilizers;
- iv. Anti-anxiety agents; and
- v. Attention deficit hyperactivity disorder stimulants

The Department's Pharmacy and Therapeutics Committee has reviewed these drug classes for inclusion on the PDL. The committee was established by UAC R414-60B-5 as a professional and technical advisory board to the Department in the formulation of a PDL. The committee is composed of physicians and pharmacists who meet regularly to consider PDL recommendations.

On July 1, 2016, the Department placed attention deficit hyperactivity disorder (ADHD) stimulants on the PDL. On October 1, 2016, the Department added atypical anti-psychotics, anti-depressants (several categories), and anti-convulsants/mood stabilizers (several categories) to the PDL. On January 1, 2017, the Department added most of the remaining anti-depressants, anti-convulsants/mood stabilizers, and anti-anxiety agents to the PDL. On January 1, 2018, the Department added anti-depressant TCA's and MAOI's to the PDL.

Savings for Fiscal Year Ended June 30, 2019

The Department achieves PDL savings by shifting utilization to less expensive drugs that are equally safe and efficacious, as well as from secondary rebates from drug manufacturers. The Department also incurs additional administrative expenses by implementing and managing the PDL which are subtracted from the PDL savings figure.

PDL savings from all psychotropic drug classes for the state fiscal year ending June 30, 2020 are \$3,020,460 in General Fund.

Provider Compliance with the PDL:

UCA 26-18-2.4(3) also requires the Department to:

(ii) Determine whether care provider compliance with the preferred drug list is at least:

- A. 55% of prescriptions by July 1, 2017;
- B. 65% of prescriptions by July 1, 2018; and
- C. 75% of prescriptions by July 1, 2019.

Compliance with the PDL at the completion of State fiscal year 2019 is 91%.